New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients

ALK and ROS1 fusions are effectively targeted by tyrosine kinase inhibitors (TKIs), however patients inevitably relapse after an initial response, often due to kinase domain mutations. We investigated circulating DNA from TKI-relapsed NSCLC patients by deep-sequencing. New EML4::ALK substitutions, L...

Full description

Saved in:
Bibliographic Details
Published in:NPJ precision oncology 2024-03, Vol.8 (1), p.29-29, Article 29
Main Authors: Villa, Matteo, Malighetti, Federica, Sala, Elisa, Sharma, Geeta G., Arosio, Giulia, Gemelli, Maria, Manfroni, Chiara, Fontana, Diletta, Cordani, Nicoletta, Meneveri, Raffaella, Zambon, Alfonso, Piazza, Rocco, Pagni, Fabio, Cortinovis, Diego, Mologni, Luca
Format: Article
Language:English
Subjects:
692/4028/67
692/4028/67/68
Biopsy
Brief Communication
Cancer Research
Cancer therapies
Chemotherapy
Cloning
Gene Therapy
Human Genetics
Inhibitor drugs
Internal Medicine
Kinases
Lung cancer
Medicine
Medicine & Public Health
Mutation
Oncology
Patients
Plasma
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c492t-1d543e092717a2bede5d856a0a8e40647cbcb72e4782a929174b25774acff9433
container_end_page 29
container_issue 1
container_start_page 29
container_title NPJ precision oncology
container_volume 8
creator Villa, Matteo
Malighetti, Federica
Sala, Elisa
Sharma, Geeta G.
Arosio, Giulia
Gemelli, Maria
Manfroni, Chiara
Fontana, Diletta
Cordani, Nicoletta
Meneveri, Raffaella
Zambon, Alfonso
Piazza, Rocco
Pagni, Fabio
Cortinovis, Diego
Mologni, Luca
description ALK and ROS1 fusions are effectively targeted by tyrosine kinase inhibitors (TKIs), however patients inevitably relapse after an initial response, often due to kinase domain mutations. We investigated circulating DNA from TKI-relapsed NSCLC patients by deep-sequencing. New EML4::ALK substitutions, L1198R, C1237Y and L1196P, were identified in the plasma of NSCLC ALK patients and characterized in a Ba/F3 cell model. Variants C1237Y and L1196P demonstrated pan-inhibitor resistance across 5 clinical and 2 investigational TKIs.
doi_str_mv 10.1038/s41698-024-00498-w
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_99f488c2e4a640108d5e08ac02e23058</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_99f488c2e4a640108d5e08ac02e23058</doaj_id><sourcerecordid>2938147002</sourcerecordid><originalsourceid>FETCH-LOGICAL-c492t-1d543e092717a2bede5d856a0a8e40647cbcb72e4782a929174b25774acff9433</originalsourceid><addsrcrecordid>eNp9kk9v1DAQxSMEolXpF-CAInHhEhj_SWz3gqqqQMUCF5C4WY4zu_Uqa29th9V-e7xNKS0HTh77vfnZY72qekngLQEm3yVOOiUboLwB4KXaPamOKVOiEZ38-fRBfVSdprQGACJbQrvueXXEJOeHzXGFX3FXb41vzhefa-evXe9yiE3E5FI2PteXXxb87OygbqZssgs-1QNmtBmHut_Xo7uZXKlc2KZ9IdTj5Fe1Nd5iLODs0Of0onq2NGPC07v1pPrx4fL7xadm8e3j1cX5orFc0dyQoeUMQVFBhKE9DtgOsu0MGIkcOi5sb3tBkQtJjaKKCN7TVghu7HKpOGMn1dXMHYJZ6210GxP3Ohinbw9CXGkTs7MjaqWWXEpbYKbjQEAOLYI0FihSBq0srPczazv1GxxsmSOa8RH0seLdtV6FX5qAIhIkL4Q3d4QYbiZMWW9csjiOxmOYkqaKUyI71h6sr_-xrsMUffmr4mKScAFAi4vOLhtDShGX968hoA-p0HMqdEmFvk2F3pWmVw_nuG_5k4FiYLMhFcmvMP69-z_Y38hpwjo</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2938147002</pqid></control><display><type>article</type><title>New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients</title><source>PubMed (Medline)</source><source>Publicly Available Content (ProQuest)</source><source>Alma/SFX Local Collection</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Villa, Matteo ; Malighetti, Federica ; Sala, Elisa ; Sharma, Geeta G. ; Arosio, Giulia ; Gemelli, Maria ; Manfroni, Chiara ; Fontana, Diletta ; Cordani, Nicoletta ; Meneveri, Raffaella ; Zambon, Alfonso ; Piazza, Rocco ; Pagni, Fabio ; Cortinovis, Diego ; Mologni, Luca</creator><creatorcontrib>Villa, Matteo ; Malighetti, Federica ; Sala, Elisa ; Sharma, Geeta G. ; Arosio, Giulia ; Gemelli, Maria ; Manfroni, Chiara ; Fontana, Diletta ; Cordani, Nicoletta ; Meneveri, Raffaella ; Zambon, Alfonso ; Piazza, Rocco ; Pagni, Fabio ; Cortinovis, Diego ; Mologni, Luca</creatorcontrib><description>ALK and ROS1 fusions are effectively targeted by tyrosine kinase inhibitors (TKIs), however patients inevitably relapse after an initial response, often due to kinase domain mutations. We investigated circulating DNA from TKI-relapsed NSCLC patients by deep-sequencing. New EML4::ALK substitutions, L1198R, C1237Y and L1196P, were identified in the plasma of NSCLC ALK patients and characterized in a Ba/F3 cell model. Variants C1237Y and L1196P demonstrated pan-inhibitor resistance across 5 clinical and 2 investigational TKIs.</description><identifier>ISSN: 2397-768X</identifier><identifier>EISSN: 2397-768X</identifier><identifier>DOI: 10.1038/s41698-024-00498-w</identifier><identifier>PMID: 38448512</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/4028/67 ; 692/4028/67/68 ; Biopsy ; Brief Communication ; Cancer Research ; Cancer therapies ; Chemotherapy ; Cloning ; Gene Therapy ; Human Genetics ; Inhibitor drugs ; Internal Medicine ; Kinases ; Lung cancer ; Medicine ; Medicine &amp; Public Health ; Mutation ; Oncology ; Patients ; Plasma</subject><ispartof>NPJ precision oncology, 2024-03, Vol.8 (1), p.29-29, Article 29</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c492t-1d543e092717a2bede5d856a0a8e40647cbcb72e4782a929174b25774acff9433</cites><orcidid>0000-0002-6534-642X ; 0009-0009-2492-8974 ; 0000-0003-1143-0252 ; 0000-0002-3227-8280 ; 0000-0003-1633-6310 ; 0000-0002-6365-5149 ; 0000-0001-7611-7369</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10918084/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2938147002?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,25734,27905,27906,36993,36994,44571,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38448512$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Villa, Matteo</creatorcontrib><creatorcontrib>Malighetti, Federica</creatorcontrib><creatorcontrib>Sala, Elisa</creatorcontrib><creatorcontrib>Sharma, Geeta G.</creatorcontrib><creatorcontrib>Arosio, Giulia</creatorcontrib><creatorcontrib>Gemelli, Maria</creatorcontrib><creatorcontrib>Manfroni, Chiara</creatorcontrib><creatorcontrib>Fontana, Diletta</creatorcontrib><creatorcontrib>Cordani, Nicoletta</creatorcontrib><creatorcontrib>Meneveri, Raffaella</creatorcontrib><creatorcontrib>Zambon, Alfonso</creatorcontrib><creatorcontrib>Piazza, Rocco</creatorcontrib><creatorcontrib>Pagni, Fabio</creatorcontrib><creatorcontrib>Cortinovis, Diego</creatorcontrib><creatorcontrib>Mologni, Luca</creatorcontrib><title>New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients</title><title>NPJ precision oncology</title><addtitle>npj Precis. Onc</addtitle><addtitle>NPJ Precis Oncol</addtitle><description>ALK and ROS1 fusions are effectively targeted by tyrosine kinase inhibitors (TKIs), however patients inevitably relapse after an initial response, often due to kinase domain mutations. We investigated circulating DNA from TKI-relapsed NSCLC patients by deep-sequencing. New EML4::ALK substitutions, L1198R, C1237Y and L1196P, were identified in the plasma of NSCLC ALK patients and characterized in a Ba/F3 cell model. Variants C1237Y and L1196P demonstrated pan-inhibitor resistance across 5 clinical and 2 investigational TKIs.</description><subject>692/4028/67</subject><subject>692/4028/67/68</subject><subject>Biopsy</subject><subject>Brief Communication</subject><subject>Cancer Research</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Cloning</subject><subject>Gene Therapy</subject><subject>Human Genetics</subject><subject>Inhibitor drugs</subject><subject>Internal Medicine</subject><subject>Kinases</subject><subject>Lung cancer</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Patients</subject><subject>Plasma</subject><issn>2397-768X</issn><issn>2397-768X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9kk9v1DAQxSMEolXpF-CAInHhEhj_SWz3gqqqQMUCF5C4WY4zu_Uqa29th9V-e7xNKS0HTh77vfnZY72qekngLQEm3yVOOiUboLwB4KXaPamOKVOiEZ38-fRBfVSdprQGACJbQrvueXXEJOeHzXGFX3FXb41vzhefa-evXe9yiE3E5FI2PteXXxb87OygbqZssgs-1QNmtBmHut_Xo7uZXKlc2KZ9IdTj5Fe1Nd5iLODs0Of0onq2NGPC07v1pPrx4fL7xadm8e3j1cX5orFc0dyQoeUMQVFBhKE9DtgOsu0MGIkcOi5sb3tBkQtJjaKKCN7TVghu7HKpOGMn1dXMHYJZ6210GxP3Ohinbw9CXGkTs7MjaqWWXEpbYKbjQEAOLYI0FihSBq0srPczazv1GxxsmSOa8RH0seLdtV6FX5qAIhIkL4Q3d4QYbiZMWW9csjiOxmOYkqaKUyI71h6sr_-xrsMUffmr4mKScAFAi4vOLhtDShGX968hoA-p0HMqdEmFvk2F3pWmVw_nuG_5k4FiYLMhFcmvMP69-z_Y38hpwjo</recordid><startdate>20240306</startdate><enddate>20240306</enddate><creator>Villa, Matteo</creator><creator>Malighetti, Federica</creator><creator>Sala, Elisa</creator><creator>Sharma, Geeta G.</creator><creator>Arosio, Giulia</creator><creator>Gemelli, Maria</creator><creator>Manfroni, Chiara</creator><creator>Fontana, Diletta</creator><creator>Cordani, Nicoletta</creator><creator>Meneveri, Raffaella</creator><creator>Zambon, Alfonso</creator><creator>Piazza, Rocco</creator><creator>Pagni, Fabio</creator><creator>Cortinovis, Diego</creator><creator>Mologni, Luca</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><general>Nature Portfolio</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-6534-642X</orcidid><orcidid>https://orcid.org/0009-0009-2492-8974</orcidid><orcidid>https://orcid.org/0000-0003-1143-0252</orcidid><orcidid>https://orcid.org/0000-0002-3227-8280</orcidid><orcidid>https://orcid.org/0000-0003-1633-6310</orcidid><orcidid>https://orcid.org/0000-0002-6365-5149</orcidid><orcidid>https://orcid.org/0000-0001-7611-7369</orcidid></search><sort><creationdate>20240306</creationdate><title>New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients</title><author>Villa, Matteo ; Malighetti, Federica ; Sala, Elisa ; Sharma, Geeta G. ; Arosio, Giulia ; Gemelli, Maria ; Manfroni, Chiara ; Fontana, Diletta ; Cordani, Nicoletta ; Meneveri, Raffaella ; Zambon, Alfonso ; Piazza, Rocco ; Pagni, Fabio ; Cortinovis, Diego ; Mologni, Luca</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c492t-1d543e092717a2bede5d856a0a8e40647cbcb72e4782a929174b25774acff9433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>692/4028/67</topic><topic>692/4028/67/68</topic><topic>Biopsy</topic><topic>Brief Communication</topic><topic>Cancer Research</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Cloning</topic><topic>Gene Therapy</topic><topic>Human Genetics</topic><topic>Inhibitor drugs</topic><topic>Internal Medicine</topic><topic>Kinases</topic><topic>Lung cancer</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Patients</topic><topic>Plasma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Villa, Matteo</creatorcontrib><creatorcontrib>Malighetti, Federica</creatorcontrib><creatorcontrib>Sala, Elisa</creatorcontrib><creatorcontrib>Sharma, Geeta G.</creatorcontrib><creatorcontrib>Arosio, Giulia</creatorcontrib><creatorcontrib>Gemelli, Maria</creatorcontrib><creatorcontrib>Manfroni, Chiara</creatorcontrib><creatorcontrib>Fontana, Diletta</creatorcontrib><creatorcontrib>Cordani, Nicoletta</creatorcontrib><creatorcontrib>Meneveri, Raffaella</creatorcontrib><creatorcontrib>Zambon, Alfonso</creatorcontrib><creatorcontrib>Piazza, Rocco</creatorcontrib><creatorcontrib>Pagni, Fabio</creatorcontrib><creatorcontrib>Cortinovis, Diego</creatorcontrib><creatorcontrib>Mologni, Luca</creatorcontrib><collection>SpringerOpen</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database (ProQuest)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>NPJ precision oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Villa, Matteo</au><au>Malighetti, Federica</au><au>Sala, Elisa</au><au>Sharma, Geeta G.</au><au>Arosio, Giulia</au><au>Gemelli, Maria</au><au>Manfroni, Chiara</au><au>Fontana, Diletta</au><au>Cordani, Nicoletta</au><au>Meneveri, Raffaella</au><au>Zambon, Alfonso</au><au>Piazza, Rocco</au><au>Pagni, Fabio</au><au>Cortinovis, Diego</au><au>Mologni, Luca</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients</atitle><jtitle>NPJ precision oncology</jtitle><stitle>npj Precis. Onc</stitle><addtitle>NPJ Precis Oncol</addtitle><date>2024-03-06</date><risdate>2024</risdate><volume>8</volume><issue>1</issue><spage>29</spage><epage>29</epage><pages>29-29</pages><artnum>29</artnum><issn>2397-768X</issn><eissn>2397-768X</eissn><abstract>ALK and ROS1 fusions are effectively targeted by tyrosine kinase inhibitors (TKIs), however patients inevitably relapse after an initial response, often due to kinase domain mutations. We investigated circulating DNA from TKI-relapsed NSCLC patients by deep-sequencing. New EML4::ALK substitutions, L1198R, C1237Y and L1196P, were identified in the plasma of NSCLC ALK patients and characterized in a Ba/F3 cell model. Variants C1237Y and L1196P demonstrated pan-inhibitor resistance across 5 clinical and 2 investigational TKIs.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>38448512</pmid><doi>10.1038/s41698-024-00498-w</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-6534-642X</orcidid><orcidid>https://orcid.org/0009-0009-2492-8974</orcidid><orcidid>https://orcid.org/0000-0003-1143-0252</orcidid><orcidid>https://orcid.org/0000-0002-3227-8280</orcidid><orcidid>https://orcid.org/0000-0003-1633-6310</orcidid><orcidid>https://orcid.org/0000-0002-6365-5149</orcidid><orcidid>https://orcid.org/0000-0001-7611-7369</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2397-768X
ispartof NPJ precision oncology, 2024-03, Vol.8 (1), p.29-29, Article 29
issn 2397-768X
2397-768X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_99f488c2e4a640108d5e08ac02e23058
source PubMed (Medline); Publicly Available Content (ProQuest); Alma/SFX Local Collection; Springer Nature - nature.com Journals - Fully Open Access
subjects 692/4028/67
692/4028/67/68
Biopsy
Brief Communication
Cancer Research
Cancer therapies
Chemotherapy
Cloning
Gene Therapy
Human Genetics
Inhibitor drugs
Internal Medicine
Kinases
Lung cancer
Medicine
Medicine & Public Health
Mutation
Oncology
Patients
Plasma
title New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T23%3A43%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20pan-ALK%20inhibitor-resistant%20EML4::ALK%20mutations%20detected%20by%20liquid%20biopsy%20in%20lung%20cancer%20patients&rft.jtitle=NPJ%20precision%20oncology&rft.au=Villa,%20Matteo&rft.date=2024-03-06&rft.volume=8&rft.issue=1&rft.spage=29&rft.epage=29&rft.pages=29-29&rft.artnum=29&rft.issn=2397-768X&rft.eissn=2397-768X&rft_id=info:doi/10.1038/s41698-024-00498-w&rft_dat=%3Cproquest_doaj_%3E2938147002%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c492t-1d543e092717a2bede5d856a0a8e40647cbcb72e4782a929174b25774acff9433%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2938147002&rft_id=info:pmid/38448512&rfr_iscdi=true